NR2F6 Blockade as Adoptive Immune Cell Therapy for Metastatic Melanoma

Project Information

NR2F6-AIM

Grant agreement ID: 101189004

DOI

10.3030/101189004

Project closed

EC signature date 9 August 2024

Start date 1 September 2024

End date 28 February 2026

Funded under

• European Research Council (ERC)

Total cost

No data

EU contribution

€ 150 000,00

Coordinated by

MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

NR2F6-modified CAR T cells drive extrinsic immunogenic cell death and antigen-agnostic immunity in solid tumors

Author(s): Victoria Klepsch, Dominik Wolf, Gottfried Baier
Published in: Molecular Therapy Oncology, Issue 34, 2026, ISSN 2950-3299
Publisher: Elsevier BV
DOI: 10.1016/J.OMTON.2026.201189

NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors

Author(s): Dominik Humer, Victoria Klepsch, Dietmar Rieder, Isabel Hölzl, Daniel Schreiber, Viktor Lang, Jiří Koutník, Sebastian Peer, Tajana Sajinovic, Viana Wille, Anna Fürst, Dragana Savic, Gabriel Diem, Wilfried Posch, Ira-Ida Skvortsova, Anne Krogsdam, Sieghart Sopper, Sebastian Kobold, Zlatko Trajanoski, Kerstin Siegmund, Nikolaus Thuille, Thomas Gruber, Dominik Wolf, Gottfried Baier
Published in: Nature Communications, Issue 17, 2026, ISSN 2041-1723
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/S41467-026-69796-0